Drug Profile
Research programme: tubulin polymerisation inhibitors - Traws Pharma
Alternative Names: ON-015640; ON-24160Latest Information Update: 04 Apr 2024
Price :
$50
*
At a glance
- Originator Onconova Therapeutics
- Class Indoles; Small molecules; Sulfonamides; Sulfones
- Mechanism of Action Apoptosis stimulants; Tubulin polymerisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 02 Apr 2024 Trawsfynydd Therapeutics has merged with Onconova Therapeutics to form Traws Pharma
- 04 Nov 2017 No recent reports of development identified for research development in Cancer in USA
- 22 Apr 2013 Pharmacodynamics data presented at the 245th National Meeting of the American Chemical Society (ACS-2013)